Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3

Primary objective of this study will be to evaluate the safety and tolerability of APB-R3 following intravenous (IV) administration of single ascending dose in healthy participants.

The study will consist of 5 planned cohorts (1 cohort per dose level) for a total of up to 31 participants. Cohorts 1 and 2 will include 5 participants each (3 participants receiving the active and 2 participants receiving the placebo). Cohort 3 to Cohort 5 will include 7 participants each (5 participants receiving the active and 2 participants receiving the placebo).

Inclusion criteria

• Male or female, non-smoker, 18 to 60 years of age (both inclusive),
• Healthy as defined by:

• the absence of clinically significant illness and surgery within 4 weeks prior to study drug administration in the opinion of the investigator.
• the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease in the opinion of the investigator.

Exclusion criteria

• Abnormal finding at physical examination
• Evidence of clinical significant hepatic or renal impairment
• Clinically significant abnormal laboratory test results or positive serology test results for HBsAg, HCV antibody, or HIV antigen and antibody, or positive test results for COVID-19, or QuantiFERON®-TB test at screening.
• Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.